Highest-materiality recent filing
Q32 Bio Q2 net loss $8.9M; positive bempikibart Phase 2a data; $200M offering
Net loss $8.9M ($0.44/share) vs $9.5M ($0.78) in Q2 2025; R&D expense $4.3M, G&A $4.9M.
Q32 Bio prices $18.25/share offering of 6M shares and pre-funded warrants; net proceeds ~$187.6M
Offering of 6,027,399 shares at $18.25 and pre-funded warrants for 4,931,506 shares at $18.2499.
Topline results from 36-week Part B of SIGNAL-AA Phase 2a trial for bempikibart (ADX-914) in alopecia areata announced on July 13, 2026.
Mean percent reduction in SALT score from baseline of 35.3% in mITT analysis at Week 36.
Q32 Bio raises $55M in PIPE financing; proceeds for bempikibart trials
Gross proceeds ~$55M from sale of 6.725M shares at $8.00 and pre-funded warrants for 150K shares.
Q32 Bio launches $75M ATM equity offering after exhausting prior $14.2M program
Company sold all $14.2M from prior ATM program; offering terminated as of April 24, 2026.
Completed enrollment in Part B of SIGNAL-AA Phase 2a for alopecia areata; 36-week topline data expected mid-2026.
Q32 Bio raises $10.5M in registered direct offering to fund bempikibart trials
Gross proceeds of ~$10.5M from 1,666,679 common shares and pre-funded warrants for 1,025,654 shares at $3.90/share.
Q32 Bio sells complement inhibitor ADX-097 to Akebia for up to $592M total consideration
Upfront and guaranteed near-term payments of $12M ($7M at closing, $3M at 6 months, $2M milestone).
Q32 Bio Q3 net loss $7.4M; completes Part B enrollment in SIGNAL-AA; cash runway into 2027
Completed enrollment in Part B of SIGNAL-AA Phase 2a trial for alopecia areata; trial size increased to 33 patients; topline data expected mid-2026.
Q32 Bio completes enrollment in Part B of SIGNAL-AA Phase 2a trial; exceeds target to 33 patients
Enrollment completed in Part B of SIGNAL-AA Phase 2a trial for bempikibart in severe/very severe alopecia areata.
Q32 Bio CMO resigns; appoints Adrien Sipos as Interim CMO
Jason Campagna, M.D., Ph.D. resigns as Chief Medical Officer, effective July 9, 2025.
Q32 Bio receives Nasdaq delisting notice for stockholders' equity deficiency
Stockholders' equity (deficit) of ~($4.0M) as of March 31, 2025, below Nasdaq's $2.5M minimum.
Net loss $(11.0)M ($(0.90)/share) vs. net income $1.0M in Q1 2024; R&D expense $7.1M (down 28% YoY).
Q32 Bio Q4 2024 net loss $14.2M; cash $78M funds into 2H2026; bempikibart AA data encouraging
Cash and cash equivalents $78.0M as of Dec 31, 2024, expected to fund operations into 2H'26.
Q32 Bio presents positive Phase 2a results for bempikibart in alopecia areata at AAD 2025
Bempikibart showed 16% mean SALT reduction at week 24 vs 2% placebo (p=0.045) in severe/very severe AA patients.
Q32 Bio restructures to focus on bempikibart; discontinues ADX-097 renal trial, cuts workforce
Restructuring prioritizes bempikibart for alopecia areata; discontinues Phase 2 renal basket trial for ADX-097.
Q32 Bio reports mixed Phase 2a results: AA signal, AD miss
SIGNAL-AA: post-hoc analysis showed 16% mean SALT reduction vs 2% placebo at week 24 (p=0.045); 9% vs 0% achieved SALT-20.
Net loss $17.6M vs $14.0M YoY; R&D expense $14.3M (+$6.8M) on clinical costs and $4M milestone to Bristol-Myers Squibb.
Q32 Bio reports Q2 net loss of $17.0M; bempikibart AD trial enrollment completed at 121 patients
Net loss $17.0M ($1.42/share) vs $5.8M ($16.69) in Q2 2023; R&D expense rose to $13.4M from $8.0M.
Q32 Bio completes SIGNAL-AD Phase 2 enrollment; topline data expected Q4 2024
Enrolled 121 patients in SIGNAL-AD Phase 2 trial, exceeding original target of ~100.
Q32 Bio reports Q1 2024 results; cash $135.3M, pipeline on track
Cash, equivalents, and short-term investments of $135.3M as of March 31, 2024; funding into mid-2026.
Q32 Bio completes reverse merger with Homology Medicines; raises $42M in pre-closing financing
Merger closed March 25, 2024; former Homology renamed Q32 Bio Inc., trading as QTTB on Nasdaq.
Reverse stock split at 1-for-18 ratio effective at trading open on March 26, 2024; new CUSIP 746964105.
Homology stockholders approve all merger-related proposals with Q32 Bio
Stock Issuance Proposal passed: 35M for, 4.2M against, 9.3M broker non-votes.
Stockholder Kevin Welsh filed a putative class action on Feb 22, 2024 under Sections 14(a) and 20(a) alleging material omissions in the merger proxy statement.
Homology Medicines receives Nasdaq bid price deficiency notice; compliance deadline June 26, 2024
Received Nasdaq deficiency notice on Dec 29, 2023 for bid price below $1.00 for 30 consecutive business days.
Homology issues stock to Q32 holders; pre-merger Homology shareholders own ~25%, Q32 ~75%; CVR issued for legacy asset proceeds.
Homology Medicines to merge with Q32 Bio, valuing Q32 at $195M; CEO and CFO terminated
All-stock merger ascribes Q32 equity value of $195M; Homology equity ~$80M; Q32 stockholders to receive Homology common shares.
Homology Medicines cuts ~80 employees, initiates strategic review
Reduction in force of ~80 employees, including CMO Julie Jordan; CCO Michael Blum retained as consultant.
Homology Medicines appoints Albert Seymour as CEO; Arthur Tzianabos named Chairman
Albert Seymour, former CSO and President, promoted to CEO; base salary raised to $570,000, bonus target 55%.
FDA lifts clinical hold on Homology's pheNIX gene therapy trial for HMI-102 in PKU
FDA lifted clinical hold on pheNIX trial (HMI-102) for phenylketonuria; company resolved all issues from March 17, 2022 hold.
Homology closes $130M AAV manufacturing JV with Oxford; retains 20% stake plus put/call option
Homology transferred AAV manufacturing assets to Newco for 175,000 units, then sold 130,000 units to OXB for $130M cash.
FDA places Homology's pheNIX gene therapy trial for PKU on clinical hold due to elevated liver tests
FDA notified Homology on Feb 16, 2022 that HMI-102 trial is on clinical hold to modify risk mitigation for elevated liver function tests.
Homology forms AAV manufacturing JV with Oxford; receives $130M; owns 20% of Newco
Homology receives $130M upfront from Oxford Biomedica; Oxford invests $50M additional into Newco.
On April 25, 2025, Mark Iwicki provided notice of his resignation from the board of directors (the “Board”) of Q32 Bio Inc. (the “Company”), effective as of December 31, 2025
Steven Gillis, Matthew R. Patterson, Jeffrey V. Poulton and Alise S. Reicin resigned from the Board
Steven Gillis, Matthew R. Patterson, Jeffrey V. Poulton and Alise S. Reicin resigned from the Board
Steven Gillis, Matthew R. Patterson, Jeffrey V. Poulton and Alise S. Reicin resigned from the Board
Effective upon the closing of the Merger on March 25, 2024, the Board was reconstituted as follows: (i) Arthur Tzianabos and Mary Thistle (designated by Homology), and (ii) Jodie Morrison, David Grayzel, Diyong Xu, Isaac Manke, Kathleen LaPorte, Mark Iwicki and Bill Lundberg (designated by Legacy Q32).
Steven Gillis, Matthew R. Patterson, Jeffrey V. Poulton and Alise S. Reicin resigned from the Board
Effective upon the closing of the Merger on March 25, 2024, the Board was reconstituted as follows: (i) Arthur Tzianabos and Mary Thistle (designated by Homology), and (ii) Jodie Morrison, David Grayzel, Diyong Xu, Isaac Manke, Kathleen LaPorte, Mark Iwicki and Bill Lundberg (designated by Legacy Q32).
Effective upon the closing of the Merger on March 25, 2024, the Board was reconstituted as follows: (i) Arthur Tzianabos and Mary Thistle (designated by Homology), and (ii) Jodie Morrison, David Grayzel, Diyong Xu, Isaac Manke, Kathleen LaPorte, Mark Iwicki and Bill Lundberg (designated by Legacy Q32).
In addition, Mark Iwicki was appointed Chairperson of the Board.
Ms. Morrison, age 48, has served as our Chief Executive Officer and a member of the Board since completion of the Merger.
Effective upon the closing of the Merger on March 25, 2024, the Board was reconstituted as follows: (i) Arthur Tzianabos and Mary Thistle (designated by Homology), and (ii) Jodie Morrison, David Grayzel, Diyong Xu, Isaac Manke, Kathleen LaPorte, Mark Iwicki and Bill Lundberg (designated by Legacy Q32).
Effective upon the closing of the Merger on March 25, 2024, the Board was reconstituted as follows: (i) Arthur Tzianabos and Mary Thistle (designated by Homology), and (ii) Jodie Morrison, David Grayzel, Diyong Xu, Isaac Manke, Kathleen LaPorte, Mark Iwicki and Bill Lundberg (designated by Legacy Q32).
Max materiality 0.85 · Median 0.65 · Most common event other_material